Recent News

• 05.28.2025 - InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
• 05.22.2025 - InflaRx to Participate in Upcoming Investor Conferences
• 03.20.2025 - InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
• 02.18.2025 - InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
• 02.14.2025 - InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
• 02.13.2025 - InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
• 01.23.2025 - InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
• 01.15.2025 - InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Recent Filings

• 05.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.07.2025 - EX-99.1 EX-99.1
• 04.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.24.2025 - EX-99.1 EX-99.1
• 04.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.03.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.20.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 02.18.2025 - 424B5 Prospectus [Rule 424(b)(5)]